Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
暂无分享,去创建一个
G. L. Masson | D. Yarnitsky | M. Valis | H. Hartung | S. Ajroud‐Driss | W. Robberecht | G. Sobue | F. Klostermann | V. Drory | D. Liebetanz | R. Gold | B. Tackenberg | C. Sommer | K. Kaida | A. Schenone | M. Grandis | R. Barohn | J. Kissel | T. Toomsoo | N. van Geloven | K. Sharma | D. Cocito | C. Desnuelle | M. Mori | S. Kuwabara | C. Trebst | A. Meisel | L. Hobson‐Webb | V. Bril | D. Cornblath | P. Van Damme | N. Latov | T. Hagenacker | K. Yokoyama | J. Franques | P. Berlit | P. Kunc | P. Clavelou | A. Shtilbans | J. D. De Bleecker | M. Freimer | M. Dimachkie | M. Stangel | O. Mielke | J. Lawo | D. Walk | D. Menichella | F. Bergh | B. Murinson | R. Morales | S. Beydoun | E. Delmont | M. Iijima | J. Pouget | T. Yokota | J. Demeestere | M. Auranen | A. Kutschenko | Z. Stelmasiak | H. Onoue | D. Lange | R. Carne | B. Durn | R. Henderson | J. Hoeijmakers | I. Merkies | C. Faber | M. Lunn | J. Haas | K. Gross-Paju | R. Taláb | M. Schroeter | F. Bethke | O. Hoffmann | S. Morino | G. Antonini | S. Blum | I. N. van Schaik | N. Notermans | F. Eftimov | J. Léger | P. Baum | J. Klehmet | C. Goerlitz | E. Ubogu | J. Morrow | N. Visser | T. Akutsu | J. Oechtering | G. Zwolińska | S. Sorbi | D. Cazzato | J. Schmidt | D. Gosal | I. Melamed | D. Kramer | R. Chin | M. Salvadó | F. Ciccocioppo | E. Simpson | K. Gable | S. Ladha | M. Saarela | J. Kamienowski | A. Nguento | C. Schrey | T. Lavin | G. González | C. M. Infante | S. Matà | S. Attarian | C. Sommer | S. Larue | T. Kalous | A. Algom | S. Muley | I. Rubanovits | A. Testori | D. Aufauvre | Richard A. Lewis | H. Lehmann | A. K. L. R. S. R. P. J. S. C. P. M. J. T. R. M. T. I. Sabet George Roberts Carne Blum Henderson Van | A. Sabet | K. George | L. Roberts | C. D'Amour | J. Sussova | M. Bednar | U. Sorro | A. Wielanek-Bachelet | J. Zschuentzsch | M. Chatzopoulos | R. Yoon | A. Jaspert‐Grehl | D. Mueller | A. Sperfeld | A. Di Muzio | G. Lauria | M. Zibetti | T. Ohkubo | T. Kanda | M. Kawai | K. Ohyama | M. Baba | M. Tomiyama | K. Nishiyama | K. Kanai | K. Rejdak | C. Casanovas Pons | M. Antonia | J. Gamez | S. Benitez | E. C. Lai | H. Johl | S. Mumfrey | T. Rao | P. MacDonald | J. Allen | Jerzy Kamienowski | Zbigniew Stelmasiak | U. Chyrchel-Paszkiewicz | J. Kamienowski | Z. Stelmasiak | S. Ajroud-Driss | I.N. van Schaik | J. De Bleecker | C. Sommer | J. Léger | W. Robberecht | J. L. De Bleecker | Z. Stelmasiak | J. Schmidt | J. Oechtering | F. Bethke
[1] G. Vita,et al. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years , 2020, Scientific Reports.
[2] J. Johnston,et al. Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report , 2020, SAGE open medical case reports.
[3] G. L. Masson,et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial , 2018, The Lancet Neurology.
[4] C. Martinez,et al. Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US , 2017, American journal of hematology.
[5] G. Sobue,et al. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[6] W. Robberecht,et al. Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial , 2017, Journal of the peripheral nervous system : JPNS.
[7] R. Hughes,et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. , 2017, The Cochrane database of systematic reviews.
[8] Nicole Spiegl,et al. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment , 2016, BioDrugs.
[9] R. Hughes,et al. Chronic in fl ammatory demyelinating polyradiculoneuropathy: from pathology to phenotype , 2022 .
[10] R. Herzlinger,et al. Hospital for Special Surgery (A) , 2014 .
[11] W. Robberecht,et al. Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) , 2013, Journal of the peripheral nervous system : JPNS.
[12] M. Dalakas. Advances in the diagnosis, pathogenesis and treatment of CIDP , 2011, Nature Reviews Neurology.
[13] H. Hartung,et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. , 2010, Archives of neurology.
[14] H. Hartung,et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. , 2010, Archives of neurology.
[15] P. Donofrio,et al. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy , 2010, Current treatment options in neurology.
[16] J. Pollard,et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision , 2010, European journal of neurology.
[17] L. Melton,et al. Incidence and prevalence of CIDP and the association of diabetes mellitus , 2009, Neurology.
[18] J. Bankart,et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK population , 2009, Muscle & nerve.
[19] H. Hartung,et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial , 2008, The Lancet Neurology.
[20] G. Sobue,et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] J. Kehr,et al. Cholinergic regulation of vascular endothelial function by human ChAT+ T cells , 2023, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Hughes,et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England , 1999, Journal of neurology, neurosurgery, and psychiatry.